A phase 1 and randomized,placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

A phase 1 and randomized,placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

Authors:	Evanthia Galanis MD S. Keith Anderson MS Erin L. Twohy MS Xiomara W. Carrero BS Jesse G. Dixon MS David Dinh Tran MD PhD Suriya A. Jeyapalan MD MPH Daniel M. Anderson MD Timothy J. Kaufmann MD MS Ryan W. Feathers BS Caterina Giannini MD PhD Jan C. Buckner MD Panos Z. Anastasiadis PhD David Schiff MD

Affiliation:	1. Department of Oncology, Mayo Clinic, Rochester, Minnesota;2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota;3. Oncology Division, Washington University School of Medicine, St. Louis, Missouri;4. Department of Neurology, Tufts Medical Center, Boston, Massachusetts;5. Department of Hematology/Oncology, Regions Hospital, St Paul, Minnesota;6. Department of Radiology, Mayo Clinic, Rochester, Minnesota;7. Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida;8. Department of Pathology, Mayo Clinic, Rochester, Minnesota;9. Department of Neurology, University of Virginia Medical Center, Charlottesville, Virginia

Abstract:

Keywords:	bevacizumab dasatinib phase 2 trial recurrent glioblastoma Src family kinase inhibitors